Technische Universitat Braunschweig

Texas A&M University System

Universitãt Stuttgart

Medizinische Hochschule Hannover

Etat Francais Represente Par Le Delegue General Pour L'armement

Universitá Degli Studi Di Pavia

Mab Factory Gmbh

Michael Hust

Stefan Dübel

Stefan Dubel

Christophe De Romeuf

Magnus A Hook

Roland Kontermann

Christian Behrens

Meike Hutt

Lars Toleikis

Oliver Seifert

Monilola Olayioye

Holger Thie

Philippe Thullier

Elmar Jäckel

Fatih Noyan

Ya-Ping Ko

Federico Bertoglio

Thomas Schirrmann

Lisa Schmitt

Srishtee Arora

Doris Meier

Livia Visai

Jonas Zantow

Mark Schütte

The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.

Compositions and use of a fibrinogen binding motif present in EFB and COA for therapeutics and vaccines against

The invention provides a fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (T) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02 or SLA-01*0401.

Fusion protein for use in the treatment of HvG disease

The invention provides an antigen-binding protein that specifically binds to a conformational epitope formed by domain III & IV of human epidermal growth factor receptor 3 (HER3) and antigen-binding proteins which compete therewith for binding, as well as fusion protein or conjugate comprising these. The invention also provides nucleic acid molecule comprising a sequence encoding said antigen binding proteins, vectors comprising the nucleic acid, and cells and pharmaceuticals comprising the antigen binding protein, the fusion protein, the nucleic acid, or the vector. The invention also provides the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical for use as a medicament. The invention further provides a method of inhibiting tumor growth or treating cancer, comprising administering a therapeutically effective amount of the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical.

Antigen binding protein against HER3

Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analysis, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.

Recombinant anti-MUC1 antibodies

The subject of the present invention is an anti-ricin antibody and the use thereof for the treatment of an individual suffering from ricin poisoning.

Anti-ricin antibody

Growing community of inventors

Hannover, Germany

Michael Hust